Medicinova INC

MediciNova shareholders elected two directors and ratified auditors, but failed to approve a proposed increase in authorized common stock.

MediciNova, Inc. announced preliminary, unaudited financial results for fiscal year 2025, reporting its first revenue while net losses widened and cash reserves declined.

MediciNova, Inc. has entered into an equity distribution agreement with Lucid Capital Markets, LLC to sell up to $50 million of common stock through an at-the-market offering.

MediciNova, Inc. has entered into a Standby Equity Purchase Agreement with YA II PN, LTD. for up to $30 million in common stock over 36 months, providing flexible capital access.

Medicinova, Inc. announced the results of its 2025 Annual Meeting of Stockholders, confirming the election of a Class III Director, ratification of its independent auditor, and advisory approval of executive compensation and a three-year frequency for future say-on-pay votes.

MediciNova updates its investor presentation, showcasing progress in clinical trials for MN-166 and MN-001 and other partnered programs.

MediciNova, Inc. filed its Q1 2026 10-Q report, detailing financial performance, ongoing clinical trials for MN-166 and MN-001, and strategic financing agreements.

MediciNova, Inc. reported increased net losses for Q3 and the nine months ended September 30, 2025, while securing a new $30 million standby equity purchase agreement to bolster liquidity.

MediciNova, a biopharmaceutical company, reported a wider net loss in Q2 2025 due to increased research and development expenses, while securing a new equity purchase agreement for future funding.

MediciNova, Inc. announces its financial results for the first quarter of 2025, highlighting its ongoing commitment to developing MN-166 and MN-001 for neurological and fibrotic disorders.

MediciNova's Q3 2024 report shows a net loss of $2.85 million, with increased research and development expenses and no revenue, while maintaining a cash balance of $42.3 million.

MediciNova's second quarter 2024 results show a net loss of $2.6 million, with a focus on advancing clinical development programs.

MediciNova's 2024 10-K filing details the company's ongoing clinical trials and financial status, emphasizing the development of MN-166 and MN-001 for various neurological and fibrotic disorders.

MediciNova, Inc. released its 10-K annual report, detailing financial results and progress across its clinical development pipeline, with a focus on MN-166 and MN-001.

Medicinoa Inc. reports that Director Nagao Hideki acquired 44,500 stock options with an exercise price of $1.36.

Director Nicole Lemerond of Medicinova Inc. acquired 44,500 stock options with an exercise price of $1.36, vesting over four installments.

Director Carolyn Beaver reported the acquisition of stock options for 44,500 shares of Medicinova Inc. common stock.

MedicinoVa's Chief Medical Officer, Kazuko Matsuda, was granted 350,000 stock options which have fully vested due to performance criteria being met.

MEDICINOVA INC's President and CEO, Yuichi Iwaki, was granted 450,000 stock options at an exercise price of $2.1, which fully vested after meeting 2025 performance criteria.

Medicinova Inc. Director Hideki Nagao was granted 20,000 stock options with an exercise price of $1.26, vesting over four installments through June 2026.

MediciNova, Inc. has announced its 2026 Annual Meeting of Stockholders will be held on June 23, 2026, proposing a significant increase in authorized common stock.

MedicinoVA, Inc has filed a definitive proxy statement with the Securities and Exchange Commission.

MediciNova will hold its 2025 Annual Meeting of Stockholders on June 17, 2025, to vote on director election, auditor ratification, executive compensation, and the frequency of executive compensation votes.

MedicinoVA, Inc. has filed a definitive proxy statement with the U.S. Securities and Exchange Commission.

MediciNova will hold its 2024 Annual Meeting of Stockholders on June 11, 2024, to elect directors and ratify the appointment of its independent accounting firm.

MediciNova, a biopharmaceutical company, entered into a Standby Equity Purchase Agreement with YA II PN, LTD. to potentially raise up to $30.0 million, while registering 25 million shares for resale by YA.